Post Marketing Observational Study of Reformulated BeneFIX
NCT ID: NCT00835068
Last Updated: 2014-09-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
58 participants
OBSERVATIONAL
2009-01-31
2013-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B
NCT00484185
Study Evaluating BENEFIX in Previously Treated Patients With Hemophilia B
NCT00581126
Study Evaluating BeneFIX in Patients With Haemophilia B, Previously Treated With Plasma Derived Factor IX
NCT00749476
Study Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia B
NCT00364182
Study Evaluating rFIX; BeneFIX® in Hemophilia B
NCT00093171
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BeneFIX
No intervention
As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects who have dated and signed the informed consent form.
Exclusion Criteria
* Participation in the European prospective registry of patients with Hemophilia B treated with BeneFIX (Wyeth protocol 3090A-101039).
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Chamberry, Cedex, France
Pfizer Investigational Site
Le Chesnay, Cedex, France
Pfizer Investigational Site
Caen, , France
Pfizer Investigational Site
Clermont-Ferrand, , France
Pfizer Investigational Site
Dijon, , France
Pfizer Investigational Site
leKremlin-Bicetre, , France
Pfizer Investigational Site
Lyon, , France
Pfizer Investigational Site
Marseille, , France
Pfizer Investigational Site
Montmorency, , France
Pfizer Investigational Site
Montpellier, , France
Pfizer Investigational Site
Nantes, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Paris, , France
Pfizer Investigational Site
Rouen, , France
Pfizer Investigational Site
Saint-Priest-en-Jarez, , France
Pfizer Investigational Site
Tours, , France
Pfizer Investigational Site
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B1821007
Identifier Type: -
Identifier Source: secondary_id
3090X1-4409
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.